Physician profile
Marco Vela
NPI 1447300579
$1,815.88
in general payments reported to CMS, 2019-2025
15 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.21 · 2023: $17.16 · 2024: $725 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,794.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $589.39 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Corcept Therapeutics | $337.01 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $250.00 | 2024-2025 | |
| Novo Nordisk INC | $160.89 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $113.14 | 2024 | Repatha, Otezla |
| Lilly USA, LLC | $59.80 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Sumitomo Pharma America, INC. | $56.38 | 2025 | Gemtesa |
| Ardelyx, INC. | $52.56 | 2025 | Ibsrela |
| Exact Sciences Corporation | $44.53 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $34.48 | 2024-2025 | Arexvy, Shingrix |
| Pfizer INC. | $32.33 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $29.95 | 2025 | |
| Janssen Pharmaceuticals, INC | $21.21 | 2022 | |
| Abbott Laboratories | $17.16 | 2023 | Freestyle Libre |
| Paratek Pharmaceuticals, INC. | $17.05 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Vela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.